Cargando…

Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy

This protocol describes the application of a mechanistic mathematical model of immune checkpoint inhibitor (ICI) immunotherapy to patient tumor imaging data for predicting solid tumor response and patient survival under ICI intervention. We describe steps for data collection and processing, data pip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butner, Joseph D., Farhat, Maguy, Cristini, Vittorio, Chung, Caroline, Wang, Zhihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719106/ https://www.ncbi.nlm.nih.gov/pubmed/36595890 http://dx.doi.org/10.1016/j.xpro.2022.101886

Ejemplares similares

Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy
por: Butner, Joseph D., et al.
Publicado: (2020)

A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden
por: Butner, Joseph D, et al.
Publicado: (2021)

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
por: Butner, Joseph D, et al.
Publicado: (2021)

A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery
por: Dogra, Prashant, et al.
Publicado: (2020)

Mathematical modeling in cancer nanomedicine: a review
por: Dogra, Prashant, et al.
Publicado: (2019)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

A multiscale agent-based model of ductal carcinoma in situ
por: Butner, Joseph D., et al.
Publicado: (2019)

Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies
por: Dogra, Prashant, et al.
Publicado: (2020)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study
por: Gravis, Gwenaelle, et al.
Publicado: (2023)

Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
por: Hung, Hao-Chien, et al.
Publicado: (2021)

Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial
por: da Silva Lopes, André Manuel, et al.
Publicado: (2023)

Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer
por: Antill, Yoland, et al.
Publicado: (2021)

New Challenges in the Diagnosis of Kidney Damage Due to Immune Checkpoint Inhibitors Therapy: An Observational Clinical Study
por: Vicente-Vicente, Laura, et al.
Publicado: (2023)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
por: Dobosz, Paula, et al.
Publicado: (2022)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Safety and Efficacy of Bojungikki-Tang in Advanced NSCLC Patients Receiving Treatment with Immune Checkpoint Inhibitors: Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Trial
por: Ko, Mi Mi, et al.
Publicado: (2023)

An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial
por: Fraterman, Itske, et al.
Publicado: (2023)

Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer
por: Dogra, Prashant, et al.
Publicado: (2022)

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
por: Ibrahim, Rebecca, et al.
Publicado: (2023)

Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study
por: Daoussis, Dimitrios, et al.
Publicado: (2020)

Innate immunity plays a key role in controlling viral load in COVID-19: mechanistic insights from a whole-body infection dynamics model
por: Dogra, Prashant, et al.
Publicado: (2020)

Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model
por: Dogra, Prashant, et al.
Publicado: (2020)

Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study
por: Delombaerde, Danielle, et al.
Publicado: (2023)

Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses
por: Wang, Ying, et al.
Publicado: (2019)

The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy
por: Thompson, Nicola A., et al.
Publicado: (2022)

Protocol for identifying immune checkpoint on circulating tumor cells of human pancreatic ductal adenocarcinoma by single-cell RNA sequencing
por: Liu, Xiaowei, et al.
Publicado: (2023)

Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer
por: Foy, Susan P, et al.
Publicado: (2014)

Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer
por: Dine, Jennifer, et al.
Publicado: (2017)

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
por: Franzese, Ornella, et al.
Publicado: (2017)

Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors
por: Tateo, Valentina, et al.
Publicado: (2020)

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Qiu, Hui, et al.
Publicado: (2021)

Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects
por: Chen, Xunrui, et al.
Publicado: (2022)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Shen, Pan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_89kv11pcjf03ruges6f20aim7a